LCM
ADMA icon

Laurion Capital Management’s ADMA Biologics ADMA Stock Holding History

Laurion Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-878,092
Closed -$2.53M – 886
2020
Q1 		$2.53M Buy
+878,092
New +$3.04M 0.03% 324

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Laurion Capital Management's ADMA Position: Q2 2020 in Review

Laurion Capital Management sold out of ADMA Biologics (ADMA) in Q2 2020, closing a stake of 878,092 shares — an estimated $2.53M sold.

Laurion Capital Management first reported a position in ADMA in Q1 2020 and held it in 1 quarter. The position peaked at $2.53M in Q1 2020. 95 funds tracked by Wall St. Rank hold ADMA as of Q2 2020.

  • Laurion Capital Management reported no remaining ADMA Biologics position as of Q2 2020 after selling out during the quarter.
  • Laurion Capital Management sold 878,092 ADMA Biologics shares in Q2 2020, an estimated $2.53M.
  • Laurion Capital Management first reported a position in ADMA Biologics in Q1 2020 and held it in 1 quarter.
  • Laurion Capital Management's ADMA Biologics position peaked at $2.53M in Q1 2020.
  • 95 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2020.

Based on Laurion Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.